Holen Sie sich die Stockscreener-App
1.91
2.69%
0.05
Vorhandelsmarkt:
1.91
Schlusskurs vom Vortag:
$1.86
Offen:
$1.89
24-Stunden-Volumen:
13,911
Relative Volume:
0.33
Marktkapitalisierung:
$96.59M
Einnahmen:
$134.00K
Nettoeinkommen (Verlust:
$-9.93M
KGV:
-5.6176
EPS:
-0.34
Netto-Cashflow:
$-6.72M
1W Leistung:
-3.05%
1M Leistung:
-1.55%
6M Leistung:
-15.11%
1J Leistung:
+11.70%
1-Tages-Spanne:
$1.8712
$1.94
1-Wochen-Bereich:
$1.8401
$2.04
52-Wochen-Spanne:
$1.41
$2.79
Entera Bio Ltd Stock (ENTX) Company Profile
Firmenname
Entera Bio Ltd
Sektor
Branche
Telefon
972-2-532-7151
Adresse
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Vergleichen Sie ENTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.91 | 96.59M | 134.00K | -9.93M | -6.72M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-22 | Eingeleitet | Aegis Capital | Buy |
Entera Bio Ltd Aktie (ENTX) Neueste Nachrichten
Northern Trust Corp Acquires New Position in Entera Bio Ltd. (NASDAQ:ENTX) - Defense World
Entera Bio (ENTX) Registers $100 Million Mixed Securities Shelf Offering | ENTX Stock News - GuruFocus
Entera Bio Files $100 Million Mixed Shelf - marketscreener.com
Financial Comparison: Entera Bio (NASDAQ:ENTX) versus Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Entera Bio Reports Q1 2025 Financial Results and Strategic Developments - TipRanks
Entera Bio Reports Q1 2025 Results and Strategic Updates - TipRanks
Entera Bio Ltd. Reports Q1 2025 Financial Results and Business Updates, Advances Oral Osteoporosis Treatment and Partnerships - Nasdaq
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Entera Bio Ltd expected to post a loss of 7 cents a shareEarnings Preview - TradingView
Entera Bio (ENTX) to Release Earnings on Friday - Defense World
Entera Bio (NASDAQ:ENTX) Trading Up 5.6% – Time to Buy? - Defense World
Entera Bio reports positive phase 2 results for osteoporosis treatment By Investing.com - Investing.com South Africa
Entera Bio reports positive phase 2 results for osteoporosis treatment - Investing.com
Game-Changing Oral Osteoporosis Treatment Matches Injectable Efficacy in Clinical Trial - Stock Titan
Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with OsteoporosisHighlighted as Oral Presentation at WCO-IOF ESCEO - GlobeNewswire
Entera Bio Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Entera Bio (NASDAQ:ENTX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Entera Bio Reports Transformative Year in 2024 - TipRanks
Entera Bio Ltd. (ENTX) reports earnings - Quartz
Entera Bio Announces 2024 Financial Results and Updates - TipRanks
Entera Bio's Breakthrough: Oral Peptide Programs Show Promise as 2024 Results Reveal $21M War Chest - Stock Titan
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
Entera Bio Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Entera Bio’s (ENTX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
OPKO And Entera Bio Team Up For Game-Changing Obesity Pill - Finimize
Opko Health, Entera Bio sign agreement for oral GLP-1/glucagon dual agonist peptide - BioWorld MedTech
OPKO and Entera team up on oral obesity candidate - The Pharma Letter
OPKO and Entera Bio partner on oral obesity treatment By Investing.com - Investing.com Australia
OPKO and Entera partner to develop obesity pill -March 17, 2025 at 08:54 am EDT - Marketscreener.com
Entera Bio Collaborates with OPKO for Oral GLP-1/Glucagon - TipRanks
OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity -March 17, 2025 at 08:38 am EDT - Marketscreener.com
OPKO and Entera Bio partner on oral obesity treatment - Investing.com India
OPKO Health and Entera Bio Enter into Collaboration - GlobeNewswire
OPKO Health (OPK) and Entera Bio (ENTX) Enter into Collaboration Agreement - StreetInsider
Revolutionary Oral GLP-1 Obesity Treatment: OPKO and Entera Join Forces to Challenge Injectable Market - StockTitan
Entera Bio (ENTX) Expected to Announce Quarterly Earnings on Friday - Defense World
Entera Bio Ltd. to Host Earnings Call - ACCESS Newswire
Entera Bio to Participate in Upcoming Events - GlobeNewswire
Can Entera Bio's Upcoming Scientific Data Reshape Oral Peptide Therapy? Major Conference Schedule Revealed - Stock Titan
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskel - The Manila Times
Could This Oral Osteoporosis Treatment Replace Daily Injections? Phase 2 Data Reveals Promising Results - StockTitan
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 31.6% in January - MarketBeat
US Penny Stocks: 3 Picks With Market Caps Over $60M - Yahoo Finance
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Increase in Short Interest - MarketBeat
Finanzdaten der Entera Bio Ltd-Aktie (ENTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):